PIL Readability Testing is Mandatory in EAEUFebruary 15, 2022
Automation in pharmaceutical manufacturing helps you comply with the new requirements of EAEU GMP Rules with minimal effort
The updated Annex 15 of the EAEU GMP came into effect on June 14, 2021, by Decision of the EEC Council No. 65. The new requirements significantly increase the workload on quality management specialists in pharma. Inpharmatis experts believe that the automation of the quality management system (QMS) will largely reduce the costs to manufacture medicine.
“It is important to note that retrospective validation is no longer allowed pursuant to Annex 15 of the EAEU GMP Rules. Any changes that could affect product quality are documented and their impact on the validation status is assessed. Personnel must be properly trained to follow the required procedures. The requirement to ensure data integrity in the pharmaceutical industry is emphasized separately. All documents must be duly approved by authorized persons,” says Konstantin Koshechkin, Head of Electronic Solutions at Inpharmatis
At the same time, the preparation, approval, and storage of all necessary documents in paper form will require more labor costs and resources, and cannot completely eliminate human errors. The implementation of advanced electronic solutions into manufacturing processes allows you to significantly optimize the resources that are necessary to comply with the EAEU GMP requirements. The Inpharmatis has many years of proven experience in the digitalization of pharmaceutical QMS in the EAEU and CIS. For example, eQMS DOT Compliance solution ensures full compliance with the most stringent regulatory requirements, including continuous validation.
According to Annex 15 of the EAEU GMP, decisions on the scope of validation and qualifications should be based on a substantiated and documented analysis of quality risks. QMS DOT Compliance pays special attention to this requirement since the system is based on the principles of documentation and risk analysis.
The new requirements also state that qualification and validation data that have been obtained from external sources can only be used if such an approach is justified and there is confidence that all the necessary control activities have been carried out throughout the data collection process. QMS DOT Compliance allows you to automate work with suppliers so that a pharmaceutical company can determine a set of requirements for all participants in a controlled process and automatically collect the necessary information.
The new GMP Annex 15 states that planning must include the life cycle of facilities, equipment, utilities, processes, and products. It is emphasized that personnel involved in qualification and validation must be properly trained and follow approved procedures. QMS DOT Compliance allows you to create a pharmaceutical quality system that meets these requirements. It contains a deviation management system, specifying the acceptance criteria, the application of quality risk management principles, and the chosen qualification and validation strategy, including re-qualification. The organizational structure of the company defines the roles of the employees and the corresponding procedures in which the personnel should be trained. At the same time, the electronic system will control the frequency itself of repeated training and the passage of extraordinary training when changes are made.
To comply with the new requirements of the Eurasian GMP, it is necessary that all qualification and validation documents are approved by persons authorized with powers that are indicated in the pharmaceutical quality system. QMS DOT Compliance allows you to set these rights and carry out electronic approval of documents, ensuring that it is approved only by an authorized person. Also, the electronic system can confirm the suitability and compliance with the internal procedures of the validation documentation provided by a third party. The opportunity has been implemented to supplement the validation protocols received from the validation service providers with the necessary documentation and test reports before their start.
Пользовательское тестирование по ЕАЭС – обязательная процедураFebruary 14, 2022
One More Inpharmatis Team Member Gets PhD in Pharmaceutical SciencesJanuary 27, 2022
В штате Inpharmatis стало на одного доктора фармацевтических наук большеJanuary 27, 2022
Pharma 4.0: Data-Driven RegulationJanuary 18, 2022
Pharma 4.0: от управления на основе документов к решениям, основанным на данныхJanuary 18, 2022
New Inpharmatis Russian Office Phone NumberJanuary 05, 2022
Изменение контактных данных российского офиса InpharmatisJanuary 05, 2022
Inpharmatis Team Participated in the Russian Healthcare ForumDecember 16, 2021
Inpharmatis принял участие в работе форума «Российская неделя здравоохранения»December 16, 2021